The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.

Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, Balena R

Diabetes care8 Nov 2012Cited by 93 (Europe PMC)

PMID23139373PMCIDPMC3579343DOI10.2337/dc12-0709PepBankPUB-23139373

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, exenatide reduced HbA1c less than taspoglutide 10 mg.
In plain wordsIn adults with type 2 diabetes, exenatide lowered HbA1c less than taspoglutide 10 mg.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c versus taspoglutide 10 mg
Study
n: not reported in source
Comparator
Taspoglutide 10 mg weekly
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−0.98%
exenatide 10 µg twice daily, 24 weeks
HbA1c change
−1.24%
taspoglutide 10 mg weekly comparator
HbA1c difference, taspoglutide 10 mg versus exenatide
−0.26
95% CI -0.37 to -0.15
Source sentences
Summary
Both doses of taspoglutide reduced HbA(1c) significantly more than exenatide (taspoglutide 10 mg: -1.24% [SE 0.09], difference -0.26, 95% CI -0.37 to -0.15, P < 0.0001; taspoglutide 20 mg: -1.31% [0.08], difference -0.33, -0.44 to -0.22, P < 0.0001; exenatide: -0.98% [0.08]).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was change in HbA(1c) after 24 weeks.
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937301
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, exenatide reduced HbA1c less than taspoglutide 20 mg.
In plain wordsIn adults with type 2 diabetes, exenatide lowered HbA1c less than taspoglutide 20 mg.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c versus taspoglutide 20 mg
Study
n: not reported in source
Comparator
Taspoglutide 20 mg weekly
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−0.98%
exenatide 10 µg twice daily, 24 weeks
HbA1c change
−1.31%
taspoglutide 20 mg weekly comparator
HbA1c difference, taspoglutide 20 mg versus exenatide
−0.33
95% CI -0.44 to -0.22
Source sentences
Summary
Both doses of taspoglutide reduced HbA(1c) significantly more than exenatide (taspoglutide 10 mg: -1.24% [SE 0.09], difference -0.26, 95% CI -0.37 to -0.15, P < 0.0001; taspoglutide 20 mg: -1.31% [0.08], difference -0.33, -0.44 to -0.22, P < 0.0001; exenatide: -0.98% [0.08]).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was change in HbA(1c) after 24 weeks.
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937302
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, exenatide reduced fasting plasma glucose less than taspoglutide 10 mg.
In plain wordsIn adults with diabetes, exenatide lowered fasting blood sugar less than taspoglutide 10 mg.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseFasting plasma glucose versus taspoglutide 10 mg
Study
n: not reported in source
Comparator
Taspoglutide 10 mg weekly
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Both taspoglutide doses reduced fasting plasma glucose significantly more than exenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937303
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, exenatide reduced fasting plasma glucose less than taspoglutide 20 mg.
In plain wordsIn adults with diabetes, exenatide lowered fasting blood sugar less than taspoglutide 20 mg.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseFasting plasma glucose versus taspoglutide 20 mg
Study
n: not reported in source
Comparator
Taspoglutide 20 mg weekly
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Both taspoglutide doses reduced fasting plasma glucose significantly more than exenatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937304
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, exenatide reduced weight more than taspoglutide 10 mg.
In plain wordsIn adults with diabetes, exenatide reduced weight more than taspoglutide 10 mg.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight versus taspoglutide 10 mg
Study
n: not reported in source
Comparator
Taspoglutide 10 mg weekly
Outcome group
Body weight · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Measurements
Weight change
−2.3 kg
exenatide
Weight change
−1.6 kg
taspoglutide 10 mg comparator
Source sentences
Summary
Taspoglutide reduced body weight (taspoglutide 10 mg, -1.6 kg; taspoglutide 20 mg, -2.3 kg) as did exenatide (-2.3 kg), which was greater than with taspoglutide 10 mg (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937305
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, exenatide and taspoglutide 20 mg each reduced weight by 2.3 kg.
In plain wordsIn adults with diabetes, exenatide and taspoglutide 20 mg each reduced weight by 2.3 kg.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedBody weight versus taspoglutide 20 mg
Study
n: not reported in source
Comparator
Taspoglutide 20 mg weekly
Outcome group
Body weight · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Measurements
Weight change
−2.3 kg
exenatide
Weight change
−2.3 kg
taspoglutide 20 mg comparator
Source sentences
Summary
Taspoglutide reduced body weight (taspoglutide 10 mg, -1.6 kg; taspoglutide 20 mg, -2.3 kg) as did exenatide (-2.3 kg), which was greater than with taspoglutide 10 mg (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937306
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, exenatide HbA1c effects persisted after 52 weeks.
In plain wordsIn adults with diabetes, exenatide's HbA1c reduction persisted after 52 weeks.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c effect maintenance
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
HbA(1c) and weight effects were maintained after 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Both doses of taspoglutide reduced HbA(1c) significantly more than exenatide (taspoglutide 10 mg: -1.24% [SE 0.09], difference -0.26, 95% CI -0.37 to -0.15, P < 0.0001; taspoglutide 20 mg: -1.31% [0.08], difference -0.33, -0.44 to -0.22, P < 0.0001; exenatide: -0.98% [0.08]).
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937307
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, exenatide weight effects persisted after 52 weeks.
In plain wordsIn adults with diabetes, exenatide's weight reduction persisted after 52 weeks.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight effect maintenance
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
HbA(1c) and weight effects were maintained after 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Taspoglutide reduced body weight (taspoglutide 10 mg, -1.6 kg; taspoglutide 20 mg, -2.3 kg) as did exenatide (-2.3 kg), which was greater than with taspoglutide 10 mg (P < 0.05).
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937308
09HumanRandomized controlled trialSafety outcome
In adults with diabetes, nausea occurred in 35% with exenatide versus 53% with taspoglutide 10 mg.
In plain wordsIn adults with diabetes, nausea was less common with exenatide than taspoglutide 10 mg.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNausea versus taspoglutide 10 mg
Study
n: not reported in source
Comparator
Taspoglutide 10 mg weekly
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Measurements
Nausea incidence
35%
exenatide
Nausea incidence
53%
taspoglutide 10 mg comparator
Source sentences
Summary
More adverse events with taspoglutide 10 and 20 mg than exenatide developed over time (nausea in 53, 59, and 35% and vomiting in 33, 37, and 16%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937309
10HumanRandomized controlled trialSafety outcome
In adults with diabetes, nausea occurred in 35% with exenatide versus 59% with taspoglutide 20 mg.
In plain wordsIn adults with diabetes, nausea was less common with exenatide than taspoglutide 20 mg.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNausea versus taspoglutide 20 mg
Study
n: not reported in source
Comparator
Taspoglutide 20 mg weekly
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Measurements
Nausea incidence
35%
exenatide
Nausea incidence
59%
taspoglutide 20 mg comparator
Source sentences
Summary
More adverse events with taspoglutide 10 and 20 mg than exenatide developed over time (nausea in 53, 59, and 35% and vomiting in 33, 37, and 16%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937310
11HumanRandomized controlled trialSafety outcome
In adults with diabetes, vomiting occurred in 16% with exenatide versus 33% with taspoglutide 10 mg.
In plain wordsIn adults with diabetes, vomiting was less common with exenatide than taspoglutide 10 mg.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseVomiting versus taspoglutide 10 mg
Study
n: not reported in source
Comparator
Taspoglutide 10 mg weekly
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Measurements
Vomiting incidence
16%
exenatide
Vomiting incidence
33%
taspoglutide 10 mg comparator
Source sentences
Summary
More adverse events with taspoglutide 10 and 20 mg than exenatide developed over time (nausea in 53, 59, and 35% and vomiting in 33, 37, and 16%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937311
12HumanRandomized controlled trialSafety outcome
In adults with diabetes, vomiting occurred in 16% with exenatide versus 37% with taspoglutide 20 mg.
In plain wordsIn adults with diabetes, vomiting was less common with exenatide than taspoglutide 20 mg.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseVomiting versus taspoglutide 20 mg
Study
n: not reported in source
Comparator
Taspoglutide 20 mg weekly
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Measurements
Vomiting incidence
16%
exenatide
Vomiting incidence
37%
taspoglutide 20 mg comparator
Source sentences
Summary
More adverse events with taspoglutide 10 and 20 mg than exenatide developed over time (nausea in 53, 59, and 35% and vomiting in 33, 37, and 16%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937312
13HumanRandomized controlled trialSafety outcome
In adults with diabetes, allergic reactions were less common with exenatide than taspoglutide.
In plain wordsIn adults with diabetes, allergic reactions were less common with exenatide than taspoglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAllergic reactions
Study
n: not reported in source
Comparator
Taspoglutide
Outcome group
Adverse events · Immune and inflammation
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Allergic and injection-site reactions were more common with taspoglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937313
14HumanRandomized controlled trialSafety outcome
In adults with diabetes, injection-site reactions were less common with exenatide than taspoglutide.
In plain wordsIn adults with diabetes, injection-site reactions were less common with exenatide than taspoglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInjection-site reactions
Study
n: not reported in source
Comparator
Taspoglutide
Outcome group
Adverse events · Skin and wound
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Allergic and injection-site reactions were more common with taspoglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937314
15HumanRandomized controlled trialSafety outcome
In adults with diabetes, discontinuations were lower with exenatide than taspoglutide.
In plain wordsIn adults with diabetes, fewer stopped treatment with exenatide than taspoglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDiscontinuations
Study
n: not reported in source
Comparator
Taspoglutide
Outcome group
Adverse events · Whole body
Studied dose
10 µg twice daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Discontinuations were greater with taspoglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 µg twice daily (n = 392) in an open-label, multicenter trial.
Report a problemFND-2313937315

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00717457

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Hoffmann-La Rochen = 1,189Jul 2008 to Mar 2011

Diabetes Mellitus Type 2

Trial page ClinicalTrials.govUpdated 2 Nov 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.